Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 614845, 7 pages
http://dx.doi.org/10.1155/2015/614845
Research Article

Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy

1Institute of Oncology, Davidoff Center, Rabin Medical Center, 39 Jabotinsky Street, 49100 Petah Tikva, Israel
2Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, 69978 Tel Aviv, Israel
3Radiology Department, Rabin Medical Center, 39 Jabotinsky Street, 49100 Petah Tikva, Israel
4Oncotest-Teva Pharmaceutical Industries, Ltd., Hatee’na 1, 60850 Shoham, Israel

Received 22 January 2015; Accepted 5 May 2015

Academic Editor: Murat Gokden

Copyright © 2015 Aron Popovtzer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Spiro, “Distant metastasis in adenoid cystic carcinoma of salivary origin,” American Journal of Surgery, vol. 174, no. 5, pp. 495–496, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. N. G. Chau, S. J. Hotte, E. X. Chen et al., “A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC,” Annals of Oncology, vol. 23, no. 6, pp. 1562–1570, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. B. S. Glisson, G. Blumenschein, M. Francisco, J. Erasmus, R. Zinner, and M. Kies, “Phase II trial of gefitinib in patients with incurable salivary gland cancer,” Journal of Clinical Oncology, vol. 23, abstract 5532, 2005, Proceedings of the American Society of Clinical Oncology. View at Google Scholar
  4. A. Argiris, M. A. Goldwasser, B. Burtness et al., “A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an eastern cooperative oncology group study,” Proceedings of the American Society of Clinical Oncology, vol. 24, abstract 5573, 2006. View at Google Scholar
  5. M. Agulnik, E. W. E. Cohen, R. B. Cohen et al., “Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3978–3984, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. L. D. Locati, P. Bossi, F. Perrone et al., “Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study,” Oral Oncology, vol. 45, no. 7, pp. 574–578, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Guigay, F. Bidault, S. Temam et al., “Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study,” Journal of Clinical Oncology—ASCO Annual Meeting Proceedings, vol. 25, no. 18, supplement, abstract 6086, 2007. View at Google Scholar
  8. C. H. Lin, R. F. Yen, Y. M. Jeng, C. Y. Tzen, C. Hsu, and R. L. Hong, “Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate,” Head and Neck, vol. 27, no. 12, pp. 1022–1027, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. R. Pfeffer, Y. Talmi, R. Catane, Z. Symon, A. Yosepovitch, and M. Levitt, “A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands,” Oral Oncology, vol. 43, no. 1, pp. 33–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. J. Hotte, E. W. Winquist, E. Lamont et al., “Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II Consortium Study,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 585–590, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Laurie, L. L. Siu, E. Winquist et al., “A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC clinical trials group,” Cancer, vol. 116, no. 2, pp. 362–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. J. Ross, E. M. Teoh, R. P. A'Hern et al., “Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma,” Clinical Oncology, vol. 21, no. 4, pp. 311–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Gilbert, Y. Li, H. A. Pinto et al., “Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group,” Head and Neck, vol. 28, no. 3, pp. 197–204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. L. van Herpen, L. D. Locati, J. Buter et al., “Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982),” European Journal of Cancer, vol. 44, no. 17, pp. 2542–2545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. A. Laurie, A. L. Ho, M. G. Fury, E. Sherman, and D. G. Pfister, “Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review,” The Lancet Oncology, vol. 12, no. 8, pp. 815–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. NCCN clinical practice guidelines in oncology, Head and Neck Cancers, Version 2, 2013, http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
  17. D. D. Von Hoff, J. J. Stephenson Jr., P. Rosen et al., “Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4877–4883, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. G. S. Jameson, E. Petricoin, J. C. Sachdev et al., “A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer,” Journal of Clinical Oncology, vol. 31, abstract TPS11123, 2013. View at Google Scholar
  19. M. M. Oken, R. H. Creech, D. C. Tormey et al., “Toxicity and response criteria of the Eastern Cooperative Oncology Group,” American Journal of Clinical Oncology, vol. 5, no. 6, pp. 649–655, 1982. View at Publisher · View at Google Scholar
  20. L. Friboulet, K. A. Olaussen, J.-P. Pignon et al., “ERCC1 isoform expression and DNA repair in non-small-cell lung cancer,” The New England Journal of Medicine, vol. 368, no. 12, pp. 1101–1110, 2013. View at Google Scholar · View at Scopus
  21. K. Kelly, “The benefits of achieving stable disease in advanced lung cancer,” Oncology, vol. 17, no. 7, pp. 957–970, 2003. View at Google Scholar · View at Scopus
  22. S.-F. Zhou, Y. M. Di, E. Chan et al., “Clinical pharmacogenetics and potential application in personalized medicine,” Current Drug Metabolism, vol. 9, no. 8, pp. 738–784, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer, “Immunological aspects of cancer chemotherapy,” Nature Reviews Immunology, vol. 8, no. 1, pp. 59–73, 2008. View at Publisher · View at Google Scholar · View at Scopus